MedTrace Logo

Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer

NCT00493376 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2012-02-02

No results posted yet for this study

Summary

The purpose of this study is as follows:

* to determine whether tirapazamine damages cervical tumour DNA immediately after its administration
* to determine the blood flow and oxygen level of cervical tumour before and after treatment with tirapazamine

Conditions

  • Cervix Cancer

Interventions

PROCEDURE

Cervical tissue biopsy analysis: Comet assay

Cervical tissue biopsy analysis: Comet assay

PROCEDURE

Biopsy: Measurement of histone gamma H2AX phosphorylation

Biopsy: Measurement of histone gamma H2AX phosphorylation

PROCEDURE

Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha

Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha

PROCEDURE

Measurement of vascular perfusion: contrast enhanced MRI

contrast enhanced MRI

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Christina Aquino-Parsons, MD · British Columbia Cancer Agency

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493376 on ClinicalTrials.gov